MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-01-2025
Country |
 USA |
IPO year |
1991 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
108 M |
Market Cap[1] |
$ 84.4 B |
EBITDA (LTM) |
$ 4.1 B |
P/E (LTM) |
16.86 |
P/S (LTM) |
6.05 |
EPS (LTM) |
46.47 |
Regeneron Pharmaceuticals is an American biotechnology company that specializes in the development and production of innovative medical treatments. The company was founded in 1988 in New York.
Regeneron Pharmaceuticals' main areas of focus are research and development of drugs for the treatment of various diseases, including oncological, autoimmune, infectious, and others.
One of the company's most well-known products is Eylea, which is used to treat age-related macular degeneration. In addition, Regeneron Pharmaceuticals is developing drugs for the treatment of cancer, Alzheimer's disease, Parkinson's disease, and other conditions.
The company invests heavily in scientific research and development to create innovative and effective drugs. Regeneron Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.
Regeneron Pharmaceuticals has a wide network of distributors and partners around the world, enabling it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Pharming Group N.V.
PHAR
|
$ 17.91 | -1.0 % | $ 7.59 B | Nasdaq Global Select Market |  Niderland |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.78 | -0.31 % | $ 793 M | Nasdaq Global Select Market |  Canada |
 |
Aclaris Therapeutics
ACRS
|
$ 3.03 | -0.49 % | $ 234 M | Nasdaq Global Select Market | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.09 | -4.82 % | $ 152 M | Nasdaq Global Select Market | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aptorum Group Limited
APM
|
$ 1.15 | -1.71 % | $ 6.27 M | Nasdaq Global Select Market |  China |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 209.39 | -1.61 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Aptevo Therapeutics
APVO
|
$ 0.6 | -35.8 % | $ 166 K | Nasdaq Capital Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.12 | 0.81 % | $ 7.51 B | Nasdaq Capital Market |  Australia |
 |
BioVie
BIVI
|
$ 1.2 | -5.51 % | $ 1.77 M | Nasdaq Capital Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.22 | 24.46 % | $ 479 M | NYSE American |  Israel |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 94.72 | -0.33 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 27.09 | 1.04 % | $ 1.31 B | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
$ 9.6 | 1.27 % | $ 141 M | Nasdaq Global Select Market,SPB | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Axon Enterprise
AXON
|
$ 584.81 | -1.07 % | $ 44.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 2.53 | -8.33 % | $ 30.9 M | Nasdaq Capital Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Aytu BioScience
AYTU
|
$ 2.44 | -3.56 % | $ 15.3 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 92.79 | 0.37 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 12.33 | -0.29 % | $ 812 M | Nasdaq Capital Market | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Burford Capital Limited
BUR
|
$ 9.1 | 1.0 % | $ 1.48 B | NYSE | Britain |
 |
Celldex Therapeutics
CLDX
|
$ 26.29 | -2.01 % | $ 1.69 M | Nasdaq Global Select Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.07 | 2.45 % | $ 716 M | NYSE | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.